Clearmind Medicine (CMND) Cash from Investing Activities (2023 - 2025)
Clearmind Medicine (CMND) posted quarterly Cash from Investing Activities of -$524433.0 for Q4 2025, down 49.67% year-over-year from -$1.0 million in Q4 2024, and down 564.29% quarter-over-quarter from $112954.0 in Q3 2025.
Clearmind Medicine (CMND) Cash from Investing Activities (2023 - 2025) Analysis & Trends
Clearmind Medicine's Cash from Investing Activities history runs 3 years deep, the most recent figure standing at -$524433.0 for Q4 2025.
- In Q4 2025, Cash from Investing Activities fell 49.67% year-over-year to -$524433.0; the TTM figure through Oct 2025 stood at -$542017.0 (changed N/A YoY), while the FY2025 annual figure was -$542017.0, down 127.65% from the prior year.
- Cash from Investing Activities for Q4 2025 stood at -$524433.0, down from $112954.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $112954.0 in Q3 2025, with the low at -$524433.0 in Q4 2025.
- The 3-year median for Cash from Investing Activities is -$33914.0 (2023), against an average of -$127504.0.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities slumped 933.2% in 2024, then surged 234.15% in 2025.
- Clearmind Medicine's Cash from Investing Activities stood at -$33914.0 in 2023, then plunged by 933.2% to -$350400.0 in 2024, then sank by 49.67% to -$524433.0 in 2025.
- Business Quant data shows CMND's Cash from Investing Activities at -$524433.0 in Q4 2025, $112954.0 in Q3 2025, and -$200000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Clearmind Medicine | 537,435.54 | -13.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2025 | -524,433.00 |
| Oct 31, 2025 | -524,433.00 |
| Jul 31, 2025 | 112,954.00 |
| Jul 31, 2025 | 112,954.00 |
| Apr 30, 2025 | -200,000.00 |
| Apr 30, 2025 | -200,000.00 |
| Jan 31, 2025 | 69,462.00 |
| Jan 31, 2025 | 69,462.00 |
| Oct 31, 2024 | -350,400.00 |
| Oct 31, 2024 | -350,400.00 |
| Jul 31, 2024 | 33,803.00 |
| Jul 31, 2024 | 33,803.00 |
| Oct 31, 2023 | -33,914.00 |
| Oct 31, 2023 | -33,914.00 |